Paul Allen ’s death shines light on non-Hodgkin lymphoma
The co-founder of Microsoft died Monday from complications with the disease, which is one of the most common cancers in the United States (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 16, 2018 Category: Consumer Health News Source Type: news

Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping po...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Cancer in Adolescence and Young Adulthood Linked to Endocrine Disease (CME/CE)
(MedPage Today) -- Association was strongest for leukemia, Hodgkin lymphoma, and brain cancer (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - June 29, 2018 Category: Endocrinology Source Type: news

VHIO is the first Spanish site to conduct CAR T cell trial against lymphoma in Europe
(Vall d'Hebron Institute of Oncology) Launched: First international clinical trial with CAR T cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma (B-Cell NHL) in Europe.The trial has been designed to determine the efficacy and safety of JCAR017, a chimeric antigen receptor (CAR) T cell therapy, in the treatment of clinically selected adult patients with relapsed or refractory disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2018 Category: International Medicine & Public Health Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Approval of Brentuximab Vedotin With Chemo Offers New Hope for Stage III/IV Hodgkin Lymphoma
Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years. (Source: CancerNetwork)
Source: CancerNetwork - March 22, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news

For one early adopter, CAR T therapy means 18 months cancer-free and counting
For as long as he can remember, Josh Feldman has eagerly embraced the latest technology.Decades ago, his family was the first one on the block with a VCR. Years later, when television went hi-def, he acquired a big-screen TV and signed up for HD service.So after he was diagnosed with lymphoma, it was only natural that Feldman was driven to join clinical trials for a promising new treatment. He would become one of the first UCLA Health patients to receive CAR T therapy. When nothing else worked, the treatment beat back cancer and filled his life with new hope.“Years ago, while doing my own reading after my diagnosis, ...
Source: UCLA Newsroom: Health Sciences - February 14, 2018 Category: Universities & Medical Training Source Type: news

Engineered Tumor-Specific T-Cells May Help Relapsed Hodgkin Lymphoma Patients
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T-cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news

Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma
(Children's National Health System) A research team that includes Children's National Health System clinician-researchers has validated a way to outfox tumors. They engineered T-cells, essential players in the body's own immune system, to strip tumors of their self-preservation skill and were able to hold Hodgkin lymphoma at bay in patients with relapsed disease for more than four years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2018 Category: International Medicine & Public Health Source Type: news

Wife who nursed husband through cancer developed disease
Jenny Thirlaway, 46, cared for husband Scott, 43, who had Hodgkin lymphoma. Then Jenny's ordeal began in February this year when she was diagnosed with bowel disease. (Source: the Mail online | Health)
Source: the Mail online | Health - December 18, 2017 Category: Consumer Health News Source Type: news

How Do You Perform the Adams Forward Bend Test?
Discussion Scoliosis is a lateral and rotational curvature of the spine from a plumb line hanging from C7 to the floor. Idiopathic scoliosis is the most common form. A review of scoliosis and its differential diagnosis can be found here. Depending on the age, 2-4% of adolescents have a positive Adams Forward Bend Test when assessed and ~2% may have idiopathic scoliosis of> 10 degrees. Curve progression relates to the magnitude of the curve and the patient’s age. Thus increased risk of progression occurs in patients with higher curvature magnitude at diagnosis, females (earlier start of puberty and therefore poss...
Source: PediatricEducation.org - December 4, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

GST makes ‘orphan drugs’ prices soar
These high-value ‘orphan’ drugs used in bone marrow transplant, classical Hodgkin Lymphoma, Crohn’s disease and melanoma. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 24, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Gene Therapy Tested In Boston To Treat Adults With Lymphoma
TRENTON, N.J. (CBS/AP) — U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults. The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals. That Novartis treatment was tested in Boston. In those tests, Dana Farber and Brigham and Women’s Hospital cancer researchers found that 80 percent of lymphoma patients who underwent the treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 19, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Healthwatch Local News blood cancer Brigham and Women's Hospital Dana Farber FDA Gene Therapy Novartis Pharmaceuticals Source Type: news

Nigeria: Nigerian Doctor, Donald Nwosu Battles Deadly Cancer
[This Day] As public health physician, Donald Nwosu battles a rare type of cancer, Non-Hodgkins Lymphoma, Martins Ifijeh chronicles his fight to overcome the deadly disease, adding that he urgently needs help in order to survive it (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 20, 2017 Category: African Health Source Type: news

This 11-Year-Old Is One Of The Youngest Certified Yoga Teachers In America
Tabay Atkins is one of the youngest certified yoga instructors in the country. He received the first of his four yoga certifications just a week before his 11th birthday last August. HuffPost spoke Wednesday with Tabay and his mom, Sahel Anvarinejad, whose battle with cancer first inspired Tabay to get involved with the practice.  Tabay, who is currently on a working vacay in Maui, Hawaii, with his family, was just 6 years old when his mother was diagnosed with Non-Hodgkin’s lymphoma.  In 2012, just two weeks after Anvarinejad’s recovery from the disease ― which hampered her ability to walk, among o...
Source: Healthy Living - The Huffington Post - June 22, 2017 Category: Consumer Health News Source Type: news

Latest Keytruda Approval Promising for Mesothelioma Patients
The U.S. Food and Drug Administration (FDA) expanded its approval of pembrolizumab for first-line treatment of metastatic non-small cell lung cancer last week, moving it closer to becoming a viable treatment option for patients with pleural mesothelioma. Pembrolizumab is marketed by Merck & Co. under the brand name Keytruda. It helps the body’s immune system detect and destroy cancer cells. The FDA approved its first-line use in combination with pemetrexed and carboplatin, two chemotherapy agents used regularly for mesothelioma. Pembrolizumab, the most well-known immunotherapy drug, is being studied for use with...
Source: Asbestos and Mesothelioma News - May 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: carboplatin chemotherapy for mesothelioma Dr. Raymond Wong Dr. Tawee Tanvetyanon FDA approval Keytruda first line treatment for mesothelioma Hodgkin lymphoma jimmy carter keytruda clinical trial keytruda for mesothelioma melanoma Mer Source Type: news

Moms Exposed To Monsanto Weed Killer Means Bad Outcomes For Babies
Concerns about the world’s most widely used herbicide are taking a new twist as researchers unveil data that indicates pervasive use of Monsanto Co.’s weed killer could be linked to pregnancy problems. Researchers looking at exposure to the herbicide known as glyphosate, the key ingredient in Monsanto’s Roundup-branded herbicides, said they tested and tracked 69 expectant mothers and found that the presence of glyphosate levels in their bodily fluids correlated with unfavorable birth outcomes. The research is still in preliminary stages and the sample size is small, but the team is scheduled to present th...
Source: Healthy Living - The Huffington Post - April 4, 2017 Category: Consumer Health News Source Type: news

Spencer gets back on the court after cancer
For much of his 17 years, Spencer Riley has lived to play basketball. This winter, his favorite sport helped the teenager get back to life. Riley was diagnosed with non-Hodgkin lymphoma in 2016 and treated at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center that summer. He underwent an intensive three-month treatment cycle: one week of inpatient chemotherapy at Boston Children’s Hospital, two weeks of recuperation at home, and then back to Boston Children’s. While occasionally well enough to go on family outings, he was still too weak to shoot or even dribble a basketball. But the game was ...
Source: Thrive, Children's Hospital Boston - March 29, 2017 Category: Pediatrics Authors: Saul Wisnia Tags: Diseases & Conditions Our Patients’ Stories Dana-Farber/Boston Children's Cancer and Blood Disorders Center Dr. Dan Benedetti non-Hodgkin lymphoma Source Type: news

ICR study reports Hodgkin lymphoma survivors at high risk of second cancers
A new study conducted by UK-based Institute of Cancer Research (ICR) has revealed that Hodgkin lymphoma survivors are at high risk of developing a second type of cancer, especially if they have a family history of the disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 14, 2017 Category: Pharmaceuticals Source Type: news

Hodgkin Lymphoma Survivors Face Risk of Second Cancer
Those diagnosed at younger age or have a family history of cancer even more vulnerable Source: HealthDay Related MedlinePlus Page: Hodgkin Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 13, 2017 Category: Consumer Health News Source Type: news

Hodgkin lymphoma survivors at high risk of second cancers
Patients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 13, 2017 Category: Science Source Type: news

Hodgkin lymphoma survivors at high risk of second cancers
(Institute of Cancer Research) Patients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 13, 2017 Category: Cancer & Oncology Source Type: news

UNC Lineberger launches innovative cellular immunotherapy program
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center has opened two cellular immunotherapy trials. The early-stage CAR-T trials are for patients with either Hodgkin lymphoma or non-Hodgkin lymphoma, who lack other treatment options or are at high risk of their disease returning. Researchers are working to open trials for other cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 28, 2017 Category: Global & Universal Source Type: news

Africa: Hodgkin's Lymphoma - an Uncommon Cancer That's Easily Missed in Africa
[The Conversation Africa] Hodgkin's lymphoma is an uncommon cancer that targets the immune system. It starts off as a painless swelling in the neck, armpit or groin. The Conversation Africa's health editor Joy Wanja Muraya asked Professor Nicholas Abinya to explain the disease, its stages of development and treatment. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 17, 2017 Category: African Health Source Type: news

Veterans Exposed To Contaminated Water At Marine Base To Receive Disability Benefits
WASHINGTON, Jan 12 (Reuters) - The Obama administration has agreed to provide disability benefits to military veterans exposed to contaminated drinking water while at Camp Lejeune in North Carolina, according to an official notice published on Thursday. Veterans, former reservists and former National Guard members who served for at least 30 days at the U.S. Marine Corps Base from 1953 to 1987 and have been diagnosed with one of eight diseases are eligible, according to the document published in the Federal Register, the government’s official journal. The Associated Press, which first reported the story, said the esti...
Source: Healthy Living - The Huffington Post - January 13, 2017 Category: Consumer Health News Source Type: news

VA ’s Rule Establishes a Presumption of Service Connection for Diseases Associated with Exposure to Contaminants in the Water Supply at Camp Lejeune
The U.S. Department of Veterans Affairs (VA) announced that it has established a presumption of service connection for eight diseases that may be associated with exposure to contamination in the water supply at Camp Lejeune in North Carolina from August 1, 1953 to December 31, 1987. This will make it easier for veterans to receive the care and benefits they need. The eight diseases are adult leukemia, aplastic anemia and other myelodysplatic syndromes, bladder, kidney, or liver cancer, multiple myeloma, non-Hodgkin's lymphoma, and Parkinson's disease. (Source: News stories via the Rural Assistance Center)
Source: News stories via the Rural Assistance Center - January 13, 2017 Category: Rural Health Source Type: news

Cancer Facts and Figures: Death Rate Down 25% Since 1991
By Stacy Simon The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society. The cancer death rate for men and women combined fell 25% from its peak in 1991 to 2014, the most recent year for which data are available. This decline translates to more than 2.1 million deaths averted during this time period. “Cancer Statistics, 2017,” published in the American Cancer Society’s journal CA: A Cancer Journal for Clinicians, estimates the numbers of new cancer cases and deaths expected in the US this year. The estimat...
Source: American Cancer Society :: News and Features - January 5, 2017 Category: Cancer & Oncology Tags: General Information Source Type: news

NIAID research aids discovery of genetic immune disorder
(NIH/National Institute of Allergy and Infectious Diseases) NIAID investigators and international colleagues have identified a genetic immune disorder characterized by increased susceptibility and poor immune control of Epstein-Barr virus (EBV) and, in some cases, an EBV-associated cancer called Hodgkin's lymphoma. The researchers studied two unrelated sets of siblings with similar immune problems and determined their symptoms were likely caused by a lack of CD70, a protein found on the surface of several types of immune cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 23, 2016 Category: Cancer & Oncology Source Type: news

Seattle cancer center bets big on experimental T-cell immunotherapy
Suzanne McCarroll, a television news reporter in Denver, had been in remission from non-Hodgkin lymphoma for almost eight years when the cancer returned in May 2015. She had a stem-cell transplant, but the disease came back again in January. What, she wondered, should she do now? After talking to her doctor and her brother, a […]Related:Children’s sleeplessness may be linked to bedtime use of electronic gadgetsOpioid pills ‘are like guns': More than 13,000 children were poisoned during six-year periodNew data shows a deadly measles complication is more common than thought (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - November 1, 2016 Category: Consumer Health News Source Type: news

September Is Childhood Obesity Month -- Get The Facts
The obesity epidemic continues to dominate headlines--and for good reason. Obesity is a leading cause of heart disease, diabetes, high blood pressure, and stroke. Many of these conditions occur in adults but often begin in childhood. This September is National Childhood Obesity Awareness Month. By knowing the facts and taking steps to help your children live a healthier lifestyle, childhood obesity and its resulting complications may be prevented. The Facts According to the Centers for Disease Control & Prevention (CDC), one in three children in the U.S. is overweight or obese. Childhood obesity doubled in children ...
Source: Healthy Living - The Huffington Post - September 28, 2016 Category: Consumer Health News Source Type: news

Hodgkin Lymphoma Patients Have High Fatigue Levels Regardless of Tumor Stage
Patients with Hodgkin lymphoma have a high incidence of severe acute and persistent fatigue, regardless of their tumor stage or the treatment method chosen for their disease. (Source: CancerNetwork)
Source: CancerNetwork - September 18, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Make the Diagnosis: Mysterious Mass
(MedPage Today) -- Case Findings: A 40-year-old male presents with a painful mass on his left shoulder of 5 months'duration. He has a history of stage IV scleronodular type of Hodgkin's disease that was treated 23 years ago with chemotherapy and radiation therapy. He relapsed a year later, and required another round of chemotherapy followed by autologous hematopoietic stem cell transplantation. He relapsed again the next year, and underwent another chemotherapy regimen and allogeneic stem cell transplantation. He has been disease-free for 20 years. What is your diagnosis? (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 13, 2016 Category: Gastroenterology Source Type: news

Does Roundup Cause Cancer?
It's one thing for a presidential candidate to support and defend a company that is responsible for genetically engineering organisms (GMOs) that have been banned in 38 countries. But it's quite another for a candidate to defend, invest in, or take hundreds of thousands of dollars from a company whose most successful product is the target of lawsuits that claim it causes cancer. Democratic presidential nominee Hillary Clinton has enjoyed a long, profitable relationship with Monsanto. The St. Louis-based agribusiness giant is a world leader in GMOs. It also manufactures Roundup, the popular weed killer that multiple stud...
Source: Healthy Living - The Huffington Post - September 1, 2016 Category: Consumer Health News Source Type: news

Mesothelioma Clinical Trial for Tazemetostat Launches in US
City of Hope cancer center thoracic oncologist Dr. Marianna Koczywas explains the workings of tazemetostat — the latest drug tested in a mesothelioma clinical trial — with the lock and key metaphor. “You have a specific [cancer] key, and a specific keyhole it goes through. If you can lock that keyhole, you can lock it out,” Koczywas told Asbestos.com. “These malignant cells rely on a pathway for growth and division so you try and block that specific pathway.” Koczywas is principal investigator for the mesothelioma clinical trial at the City of Hope National Medical Center in Los Angeles,...
Source: Asbestos and Mesothelioma News - August 31, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer treatment city of hope cancer center clinical trials at memorial sloan kettering clinical trials in california malignant pleural mesothelioma treatment marianna koczywas mesothelioma clinical trial tazemetostat Source Type: news

New PET device could go to your head
Researchers are developing quite the novel way to acquire PET brain scans....Read more on AuntMinnie.comRelated Reading: PET with tau agent sheds light on Alzheimer's disease SNMMI: PET shows tau may be Alzheimer's catalyst SNMMI: PET helps track neuroinflammation in MS FDG-PET helps accurately assess unconscious patients PET obviates toxic chemo for some Hodgkin's patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 24, 2016 Category: Radiology Source Type: news

Novel statistical method captures long-term health burden of pediatric cancer cures
( St. Jude Children's Research Hospital ) St. Jude Children's Research Hospital researchers have developed a metric that showed therapy-related cardiovascular disease takes a heavier toll on pediatric Hodgkin lymphoma survivors than previously recognized. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 25, 2016 Category: Cancer & Oncology Source Type: news

Five-year survival data: Brentuximab vedotin may be curative in some with Hodgkin lymphoma
(American Society of Hematology) This multinational Phase II study examines brentuximab vedotin (BV) in patients with Hodgkin lymphoma who relapsed after stem cell transplant. The study reports that 13 of 34 (38 percent) patients who achieved complete remission have remained disease-free for over five years and may be cured. Of those patients, nine received only single-agent BV. These data were published in Blood, the journal of the American Society of Hematology (ASH). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2016 Category: Global & Universal Source Type: news

Non-Hodgkin's Lymphoma
Title: Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/14/2016 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 14, 2016 Category: Cancer & Oncology Source Type: news

Nearly 1 in 12 patients with a common cancer develop a second, unrelated malignancy
UCLA researchers have identified the incidence and long-term outcomes of patients who develop second, unrelated cancers, resulting in a data set that they say sheds new light on the way cancer survivors may need to be monitored post-disease. The researchers identified more than 2.1 million patients from the Surveillance, Epidemiology and End Results database, or SEER, with the most common cancers — prostate, breast, lung, colon, rectum, bladder, uterus, kidney and melanoma and non-Hodgkin lymphoma. The team found that 8 percent of patients developed secondary cancers elsewhere, the most common of which was lung cance...
Source: UCLA Newsroom: Health Sciences - July 13, 2016 Category: Universities & Medical Training Source Type: news

What Are The Most Common Pediatric Cancers?
Discussion Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for
Source: PediatricEducation.org - July 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Finding A Cure Wouldn’t Mean We’ve Defeated Cancer
WebMD wasn't a research option when Ivy Brown was diagnosed with Hodgkin's lymphoma in 1974, so her mother looked up her 12-year-old daughter's condition the old-fashioned way, in a hardcover medical volume. "It just said 'fatal,'" Brown explained. Having moved the family to London a month earlier, Brown's parents were still trying to liaise with her pediatrician in the U.S. "My father told me recently that he was sleeping with the phone on his stomach because of the time change," she said. "They were as scared as you can be when you have a child who you think you might lose," Brown explained....
Source: Science - The Huffington Post - June 29, 2016 Category: Science Source Type: news

Finding A Cure Wouldn’t Mean We’ve Defeated Cancer
WebMD wasn't a research option when Ivy Brown was diagnosed with Hodgkin's lymphoma in 1974, so her mother looked up her 12-year-old daughter's condition the old-fashioned way, in a hardcover medical volume. "It just said 'fatal,'" Brown explained. Having moved the family to London a month earlier, Brown's parents were still trying to liaise with her pediatrician in the U.S. "My father told me recently that he was sleeping with the phone on his stomach because of the time change," she said. "They were as scared as you can be when you have a child who you think you might lose," Brown explained....
Source: Healthy Living - The Huffington Post - June 29, 2016 Category: Consumer Health News Source Type: news

When Parents Get Cancer, Children Are Often The Forgotten Victims
On the first day of spring 2007, Francesca Giessmann, 43, a marketing executive and holistic health coach from Kirkland, Washington, was rushed to the emergency room with severe stomach pain. After running numerous tests, doctors gave her the diagnosis of stage 3 non-Hodgkin lymphoma. Shocked and saddened by the news of her cancer, Giessmann's thoughts quickly turned to her son, Leo, who'd turned 3 years old the month prior. "Leo was very young and could not fully understand what was going on," Giessmann said. "Our pediatrician suggested we try to keep everything normal. I spent a great deal of time in be...
Source: Healthy Living - The Huffington Post - June 29, 2016 Category: Consumer Health News Source Type: news

Scans May Spare Some Hodgkin Lymphoma Patients from Chemo
Test finds those who might respond well, may spare others treatment side effects Source: HealthDay Related MedlinePlus Pages: Cancer Chemotherapy, Hodgkin Disease, Nuclear Scans (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 23, 2016 Category: Consumer Health News Source Type: news

Increase in obesity among pediatric Hodgkin Lymphoma patients may be linked to disease relapse
A new study used advanced imaging methods to evaluate obesity, and suggests a relationship between obesity and disease relapse. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 6, 2016 Category: Science Source Type: news

What REALLY Went Down at Stomp The Monster, the Event to Help Cancer Patients and Their Families
Stomp the Monster 5k Run and Festival 2016. Video of some runners. Stomp the Monster Website & Twitter. Photo by Lisa Lewis. You know how I love to write about events that are kid friendly? Well, that's because I'd rather write than learn how to cook. Today's adventure was attending the Stomp the Monster 5k Run and Festival. STOMP The Monster™ provides financial and other support to cancer patients, their families, and caregivers when they need it most - during their fight with the disease. They promote a healthy lifestyle with proper diet and exercise, leading by example, and provide funding for potential adv...
Source: Healthy Living - The Huffington Post - June 6, 2016 Category: Consumer Health News Source Type: news

FDA Approves New Immunotherapy Drug for Bladder Cancer
By Hope Cristol The U.S. Food and Drug Administration (FDA) gave accelerated approval to immunotherapy drug Tecentriq (atezolizumab) this week for advanced bladder cancer. It is the first new drug approval in 3 decades for the disease, which is expected to be diagnosed in about 77,000 people in the U.S. in 2016. Tecentriq is part of a new class of immunotherapy drugs called checkpoint inhibitors. This drug, given as an infusion, targets the PD-L1 protein, which some cancer cells use to evade the immune system. By blocking PD-L1, it helps immune cells recognize and attack cancer cells. In a clinical trial that led to the dr...
Source: American Cancer Society :: News and Features - May 20, 2016 Category: Cancer & Oncology Tags: Bladder Cancer Source Type: news